Elekta AB (OTCMKTS:EKTAY) Short Interest Update

Elekta AB (OTCMKTS:EKTAY) was the recipient of a large growth in short interest in July. As of July 31st, there was short interest totaling 16,311 shares, a growth of 345.3% from the July 15th total of 3,663 shares. Approximately 0.0% of the company’s stock are short sold. Based on an average daily volume of 9,444 shares, the days-to-cover ratio is currently 1.7 days.

Analyst Ratings Changes

Separately, Zacks Research upgraded shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce”.

Elekta Stock Performance

Shares of EKTAY traded up $0.15 during trading hours on Friday, hitting $5.57. The stock had a trading volume of 3,728 shares, compared to its average volume of 2,967. The firm has a 50-day moving average price of $5.14 and a 200 day moving average price of $5.75. Elekta has a fifty-two week low of $4.35 and a fifty-two week high of $6.93. The firm has a market capitalization of $2.05 billion, a price-to-earnings ratio of -34.81 and a beta of 1.01. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.68 and a current ratio of 0.87.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, May 28th. The company reported $0.06 earnings per share for the quarter. The company had revenue of $521.00 million during the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. As a group, research analysts anticipate that Elekta will post 0.43 EPS for the current year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.